La référence en hépatite C au Québec depuis 2003

Health Canada approves DAKLINZA

Published by CAPAHC on

BMS-daklinza-daclatasvir-hepatitis-C

BMS-daklinza-daclatasvir-hepatitis-CThis all-oral therapy without interferon and ribavirin was approved today by Health Canada.

Daklinza (daclatasvir) from BMS, is a INS5A inhibitor, for patients with genotype 1,2,3, with or without cirrhosis, in combination with sofosbuvir (Sovaldi), indicated for 12 or 24 weeks regimen.

Perhaps in Quebec next year.

Categories:

Related Posts

Australia is on path to eliminate HCV before 2030 for men who have sex with men

An Australian Study looked at the incidence of the Hepatitis C Virus (HCV) among men who have sex with other men (GBM) between 2015 and 2019. The study found that the incidence of HCV for Read more…

English

Hepatitis B: Frequently Asked Questions

What’s Hepatitis B? Hepatitis B is a serious liver infection caused by the HBV (hepatitis B virus). The transmission of the HBV can happen during sexual contact (vaginal, anal or oral), through infected blood or Read more…

English

Urgent steps needed to accelerate diagnosis of hepatitis-C

Rawalpindi : Having one of the highest prevalence rate of hepatitis-C in the world, Pakistan needs to work religiously both for treatment of patients and for screening of people if we want to eliminate the Read more…